Taysha Gene Therapies
TSHA
48 hedge funds and large institutions have $362M invested in Taysha Gene Therapies in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 21 increasing their positions, 11 reducing their positions, and 5 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
91% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 11
2.3% more ownership
Funds ownership: 48.33% → 50.63% (+2.3%)
2% less funds holding
Funds holding: 49 → 48 (-1)
7% less capital invested
Capital invested by funds: $389M → $362M (-$26.6M)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$15.5M |
| 2 |
JP Morgan Chase
New York
|
+$3.93M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.37M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.89M |
| 5 |
Morgan Stanley
New York
|
+$1.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
-$15.4M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$6.79M |
| 3 |
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO)
Austin,
Texas
|
-$4.64M |
| 4 |
PVI
Pura Vida Investments
New York
|
-$717K |
| 5 |
Millennium Management
New York
|
-$639K |
TSHA Hedge Fund Activity: Q3 2021 in Review
48 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q3 2021, worth a combined $362M — down 6.9% from $389M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of TSHA and 4 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 21 added.
The largest buyer was Nantahala Capital Management, adding an estimated $15.5M. The largest seller was Sands Capital Management, exiting entirely with an estimated $15.4M sold.
- 48 institutional investors held Taysha Gene Therapies (TSHA) as of Q3 2021, down from 49 in Q2 2021.
- Funds reported $362M of Taysha Gene Therapies stock for Q3 2021, down 6.9% quarter-over-quarter.
- 4 funds opened new Taysha Gene Therapies positions in Q3 2021 and 5 closed out, a net change of -1 holder.
- The largest Taysha Gene Therapies buyer in Q3 2021 was Nantahala Capital Management, an estimated $15.5M added.
- The largest Taysha Gene Therapies seller in Q3 2021 was Sands Capital Management, an estimated $15.4M sold.
Based on aggregated 13F filings for Q3 2021.